Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
"Licensing SAN711 to expand our pipeline underscores our unwavering commitment to delivering innovative therapies for patients with central nervous system disorders," said Catherine Owen Adams, Chief Executive Officer. "Essential tremor is a condition that has not seen innovation in treatment for decades, creating a compelling opportunity to address a long-overlooked need. Our work with SAN711 will draw on our deep expertise in developing and commercializing cutting-edge treatments for neurological disorders."- SAN711 is a first-in-class, highly selective GABAA-α3 positive allosteric modulator
- SAN711是首个高度选择性的GABAA-α3阳性变构调节剂
- Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026
- 正在定位于2026年开始SAN711治疗原发性震颤的2期研究
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Acadia is planning to initiate a Phase 2 study of SAN711 in essential tremor in 2026.
Acadia Pharmaceuticals Inc.（纳斯达克:ACAD）今日宣布已与Saniona（OMX:SANION）签署了独家全球许可协议，用于开发和商业化SAN711，这是首个高度选择性的GABAA-α3阳性变构调节剂。公司计划首个指示将是开发SAN711用于治疗原发性震颤，这是一种神经条件，包括身体一个或多个部分的震颤或颤动。Acadia计划于2026年启动SAN711用于原发性震颤的2期研究。
"Licensing SAN711 to expand our pipeline underscores our unwavering commitment to delivering innovative therapies for patients with central nervous system disorders," said Catherine Owen Adams, Chief Executive Officer. "Essential tremor is a condition that has not seen innovation in treatment for decades, creating a compelling opportunity to address a long-overlooked need. Our work with SAN711 will draw on our deep expertise in developing and commercializing cutting-edge treatments for neurological disorders."
“授权SAN711以扩大我们的产品线，凸显了我们致力于为患有中枢神经系统障碍的患者提供创新疗法的坚定承诺，”首席执行官凯瑟琳·欧文·亚当斯说。“原发性震颤是一个长达数十年未见治疗创新的疾病，为解决一个长期被忽视的需求创造了一个引人注目的机会。我们与SAN711的合作将依托我们在开发和商业化神经系统疾病的前沿治疗方面的深厚专业知识。”
Under the terms of the License Agreement, Saniona will receive US $28 million upfront plus potential milestone payments of up to US $582 million. In addition, Saniona is eligible to receive tiered royalties of mid-single digits to low double digits on net sales of commercial products that may result from development of SAN711. The potential milestone payments to Saniona consist of up to US $147 million subject to achievement of development and commercial milestones related to potential first and second indications, and up to US $435 million subject to achievement of thresholds of annual net sales of SAN711 worldwide. Acadia will lead further clinical development, regulatory submissions, and global commercialization efforts for SAN711 while also providing financial support for Saniona's ongoing Phase 1 study and preparations for Phase 2.
根据许可协议的条款，Saniona将获得2800万美元的预付款，以及最高58200万美元的潜在里程碑付款。此外，Saniona有资格获得一档随净销售额变化的中位数至低两位数的分层特许产品提成，该销售额可能是由于SAN711的开发而导致的商业产品销售。对于Saniona的潜在里程碑付款包括最高14700万美元，视开发和商业里程碑的实现而定，以及最高43500万美元，视SAN711全球年度净销售额达标的情况而定。Acadia将主导SAN711的进一步临床开发、监管提交和全球商业化工作，同时还将为Saniona正在进行的1期研究和2期准备提供财务支持。
译文内容由第三方软件翻译。
